These results are partly echoed by the in vivo results evaluating DCV targeting HER2 and HER3 for LMD performed by Law et al. discussed above, and results of the ongoing clinical trial supported by this preclinical work will be key in evaluating the efficacy of this treatment for LMD. The gene discussed is ERBB3; the disease is Langer mesomelic dysplasia.